Eli Lilly and Company (LLY)vsPureTech Health PLC (PRTC)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
PRTC
PureTech Health PLC
$17.40
-4.08%
HEALTHCARE · Cap: $441.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1019756% more annual revenue ($65.18B vs $6.39M). PRTC leads profitability with a 793.0% profit margin vs 31.7%. PRTC trades at a lower P/E of 10.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
PRTC
Buy51
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 793 of every $100 in revenue as profit
Revenue surging 543.0% year-over-year
Earnings expanding 61.5% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Operating margin of -2590.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : PRTC
The strongest argument for PRTC centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 793.0% and operating margin at -2590.0%. Revenue growth of 543.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : PRTC
The primary concerns for PRTC are Market Cap, Free Cash Flow, Operating Margin.
Key Dynamics to Monitor
PRTC carries more volatility with a beta of 0.71 — expect wider price swings.
PRTC is growing revenue faster at 543.0% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 51/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →PureTech Health PLC
HEALTHCARE · BIOTECHNOLOGY · USA
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops and markets drugs for inflammatory, fibrotic and immune, intractable, lymphatic and gastrointestinal, neurological and neuropsychological cancers and other diseases in the United States. The company is headquartered in Boston, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?